KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) EBITDA (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of EBITDA readings, the most recent being $244.7 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 968.9% to $244.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $263.0 million, a 394.5% increase, with the full-year FY2025 number at $263.0 million, up 394.5% from a year prior.
  • EBITDA hit $244.7 million in Q4 2025 for Biocryst Pharmaceuticals, up from $12.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $244.7 million in Q4 2025 to a low of -$75.2 million in Q2 2023.
  • Median EBITDA over the past 5 years was -$39.3 million (2022), compared with a mean of -$24.1 million.
  • Biggest five-year swings in EBITDA: tumbled 303.12% in 2022 and later soared 968.9% in 2025.
  • Biocryst Pharmaceuticals' EBITDA stood at -$17.7 million in 2021, then tumbled by 303.12% to -$71.4 million in 2022, then rose by 14.31% to -$61.2 million in 2023, then skyrocketed by 53.97% to -$28.2 million in 2024, then soared by 968.9% to $244.7 million in 2025.
  • The last three reported values for EBITDA were $244.7 million (Q4 2025), $12.4 million (Q3 2025), and $5.6 million (Q2 2025) per Business Quant data.